Introduction: Type 1 diabetes (T1DM), formerly referred to as insulin dependent diabetes mellitus (IDDM) and juvenile diabetes, is considered a chronic autoimmune disease. Over time, the disease process results in the virtually complete elimination of pancreatic beta cells and lifelong insulin deficiency. In turn, patients become dependent on daily insulin injections to maintain an acceptable level of metabolic control. It is widely accepted that T1DM is a complex, multifactorial disease in which genetic predisposition and environmental exposures promote the triggering of multiple autoimmune responses against beta cells.

Diabetes in Control is pleased to bring you an exclusive interview with Dr. Andrew Stewart. Dr. Stewart and his fellow researchers at the Icahn School of Medicine at Mount Sinai have discovered a novel combination of two classes of drugs that induces the highest rate of proliferation ever observed in adult human beta cells—the cells in the pancreas that produce insulin. The result is an important step toward a diabetes treatment that restores the body’s ability to produce insulin. 

Time in glycemic range inversely correlated to risk of developing vascular complications in patients with diabetes

Study finds relationship between diabetes and OSA cofactors in development of CVD.

Study strengthens existing dietary advice that patients should switch from products made from white flour to whole grains.

Rise Study compared gastric banding to metformin in preserving beta cell functions in people who have prediabetes.

Research shows urological issues more frequent than once thought.

Which of the following ADA statements about recommended treatment algorithms for type 2 diabetes is true?

A. The ADA algorithm includes a specific hierarchy of recommended therapies while the AACE algorithm does not.
B. The ADA’s algorithm specifies agents to be considered for cardiovascular risk reduction.
C. Both AACE and the ADA stratify the choice of initial therapy according to baseline HbA1C less than 7.5% or greater than/equal to 7.5%.
D. The risk-benefit profiles of antihyperglycemic classes are not reflected in the AACE or ADA algorithm.

Follow the link for the answer.

Have you provided all your new patients who take insulin with a prescription for Glucagon or similar product? Follow the link to see how you and your colleagues compare.

As we know, the holidays are very tough for many of our patients who have diabetes and/or obesity. They may have made some changes -- big changes -- in their eating habits, only to get in trouble over the long holiday season, then have a very difficult time getting back on track. The long holiday season can be a disaster to their health. I have found that for most, having leftovers at home wreaks havoc.